Meeting Banner
Abstract #1705

DB-1 Human Melanoma Xenograft PH and Energy State Changes During Treatment with Lonidamine Plus Melphalan

Kavindra Nath1, David S. Nelson1, Andrew M. Ho1, Stephen B. Pickup1, Rong Zhou1, Dennis B. Leeper2, Jerry D. Glickson1

1Radiology, University of Pennsylvania, Philadelphia, PA, United States; 2Radiation Oncology, Thomas Jefferson University, Philadelphia, PA, United States

Synopsis: Since acidification enhances the activity of nitrogen mustard alkylating agents, as well as of platinum drugs such as cisplatin (CPT) that act by similar mechanisms (adding substituents to and cross-linking DNA), we have evaluated the effect of lonidamine (LND)-induced tumor acidification and response of DB-1 melanoma xenografts to treatment with CPT (7.5 mg/kg, i.v.) or melphalan (LPAM; 7.5 mg/kg, i.v.). This dose of CPT had no effect on tumor growth. Only LND + LPAM produced a significant growth delay of 19.9 2.0 d compared to LND alone of 1.1 0.1 d and LPAM alone of 4.0 0.0 d. These studies point to the potential feasibility of multiple-dose treatment of systemic melanoma by combination chemotherapy with LND + LPAM.